“Long-acting growth hormone compounds may represent an advance over daily GH injections because of increased convenience and differing pharmacodynamic properties, providing the potential for improved adherence and outcomes.”
Growth Hormone Research Society Consensus Statement, 2016
While daily injections have been the reality of Growth Hormone Deficiency (GHD) treatment for decades, Versartis is actively working on new innovations to change this for patients. The company’s lead candidate, somavaratan (VRS-317), is an investigational, novel, long-acting form of recombinant human growth hormone (rhGH) initially in development for the treatment of GHD in children and adults. Somavaratan is currently in Phase 3 clinical trials for the treatment of pediatric GHD and a Phase 2 clinical trial for adult GHD.
Somavaratan is anticipated to have a number of important characteristics that may provide advances over current treatments:
- Convenient twice-monthly dosing
- Room-temperature storage*
- Fine-gauge needle autoinjector that is ready-to-use, self-priming and single-use
- Proprietary XTEN® technology, which is designed to prolong somavaratan’s treatment effect
All of these characteristics of somavaratan together have the potential to provide improved adherence and, therefore, long-term outcomes for children and adults with GHD.
- Christiansen, et al. Eur J Endocrinol. 2016 Jun;174(6).
- Kemp, et al. Drug Design, Development and Therapy 2011, 5:411-419.
- Yuen, et al. J Clin Endocinol Metab, June 2013, 98 (6):2595-2603.
- Moore, et al. J Clin Endocrinol Metab. 2016;101(3):1091-1097.
- Versartis Long-Acting Growth Hormone in Children compared To Daily rhGH (VELOCITY). https://clinicaltrials.gov/ct2/show/NCT02339090
- Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in AGHD. https://clinicaltrials.gov/ct2/show/NCT02719990
- Cleland, et al. J Pharma Sci, August 2012, 101(8):2744-2754.
3D rendering of somavaratan (VRS-317)